Creative Commons source reading · Clinical neurodiagnostics
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.
Piotr Lewczuk; Natalia Ermann; Ulf Andreasson; Christian Schultheis; Jana Podhorna; Philipp Spitzer; Juan Manuel Maler; Johannes Kornhuber; Kaj Blennow; Henrik Zetterberg
Originally published in Alzheimer's research & therapy · 2018-07-28
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD). Methods With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm. The influence of preanalytical storage procedures on the NfL in plasma was tested on samples exposed to six different conditions. Results NfL concentrations significantly increased in the samples exposed to more than one freezing/thawing cycle, and in those stored for 5 days at room temperature or at 4 °C.
Discussion
A growing body of literature postulates a potential application of the plasma concentration of the light chain of the neurofilament protein as a screening tool for neurodegeneration. In our study, the plasma NfL concentration was found to be significantly higher in the AD patients, whose diagnoses were in accordance with the pathological results of the CSF biomarkers, compared with the nondemented control subjects, whose normal cognitive status was in accordance with the unaltered results of their CSF biomarkers.
Conclusion
In conclusion, we confirmed increased concentrations of plasma NfL in Alzheimer’s disease; however, its future potential application as a biomarker will have to take its nonspecificity into account. We speculate that plasma NfL will not be able to replace the CSF biomarkers of neurodegeneration within a given diagnostic group, but it could perhaps be considered as a potential screening tool between the groups. Finally, we extended previous studies with a systematic test for the influence of the preanalytical sample handling procedures on the NfL concentrations in plasma.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
